Article

Xenon alters right ventricular function

Department of Anesthesiology, University Hospital of Aken, Aachen, Germany.
Acta Anaesthesiologica Scandinavica (Impact Factor: 2.31). 10/2008; 52(8):1056-63. DOI: 10.1111/j.1399-6576.2008.01696.x
Source: PubMed

ABSTRACT In contrast to other volatile anesthetics, xenon produces less cardiovascular depression with fewer fluctuations of various hemodynamic parameters, but reduces cardiac output (CO) in vivo. Besides an increase in left ventricular afterload and reduction of heart rate, an impairment of the right ventricular function might be an additional pathophysiological mechanism for the reduction of CO. Therefore, we used an animal model to study the effects of xenon as a supplemental anesthetic on right ventricular function, especially right ventricular afterload.
Right ventricular function was monitored with a volumetric pulmonary artery catheter in 11 pigs during general anesthesia with thiopental. Six animals received additional 70% (volume) xenon (equivalent to 0.55 MAC minimum alveolar concentration). Parameters for systolic function, afterload, and preload were calculated at baseline and during 50 min of xenon application, and in a corresponding control group. Significant differences were detected by multivariate analyses of variance for repeated measures.
Xenon reduced CO on average by 30% and increased pulmonary arterial elastance by 60%, which led to a reduction of the right ventricular ejection fraction by 25%. Whereas right ventricular preload remained stable, maximal slope of pulmonary artery pressure and the right ventricular elastance increased. No effect on the ratio of stroke work and end-diastolic volume was found.
The reduction in CO during xenon anesthesia was partly due to an impairment of the right ventricular function, mainly caused by an increased afterload, without an impairment of systolic ventricular function.

0 Followers
 · 
108 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Xenon has minimal haemodynamic side effects when compared to volatile or intravenous anaesthetics. Moreover, in in vitro and in animal experiments, xenon has been demonstrated to convey cardio- and neuroprotective effects. Neuroprotection could be advantageous in paediatric anaesthesia as there is growing concern, based on both laboratory studies and retrospective human clinical studies, that anaesthetics may trigger an injury in the developing brain, resulting in long-lasting neurodevelopmental consequences. Furthermore, xenon-mediated neuroprotection could help to prevent emergence delirium/agitation. Altogether, the beneficial haemodynamic profile combined with its putative organ-protective properties could render xenon an attractive option for anaesthesia of children undergoing cardiac catheterization. In a phase-II, mono-centre, prospective, single-blind, randomised, controlled study, we will test the hypothesis that the administration of 50% xenon as an adjuvant to general anaesthesia with sevoflurane in children undergoing elective cardiac catheterization is safe and feasible. Secondary aims include the evaluation of haemodynamic parameters during and after the procedure, emergence characteristics, and the analysis of peri-operative neuro-cognitive function. A total of 40 children ages 4 to 12 years will be recruited and randomised into two study groups, receiving either a combination of sevoflurane and xenon or sevoflurane alone. Children undergoing diagnostic or interventional cardiac catheterization are a vulnerable patient population, one particularly at risk for intra-procedural haemodynamic instability. Xenon provides remarkable haemodynamic stability and potentially has cardio- and neuroprotective properties. Unfortunately, evidence is scarce on the use of xenon in the paediatric population. Our pilot study will therefore deliver important data required for prospective future clinical trials. EudraCT: 2014-002510-23 (5 September 2014).
    Trials 12/2015; 16(1):587. DOI:10.1186/s13063-015-0587-3 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Das Edelgas Xenon konnte sowohl im Tierversuch als auch in der klinischen Anwendung seine einfache und sichere Handhabung als Narkotikum unter Beweis stellen. Neben seinen wünschenswerten pharmakokinetischen Eigenschaften bietet es eine besondere Kreislaufstabilität und potenzielle kardio- und neuroprotektive Effekte. Dennoch hat es sich bis zum heutigen Tage nicht als Routineanästhetikum durchsetzen können, insbesondere aufgrund der vergleichsweise hohen Kosten, aber auch mangels kommerziell verfügbarer Geräte zu seiner Applikation. Dieser Beitrag fasst die bisher gemachten Erfahrungen mit Xenon als Anästhetikum zusammen, zeigt die derzeit bestehenden Limitationen seines klinischen Einsatzes auf und bietet einen Ausblick auf mögliche weitere Entwicklungen, insbesondere den Einsatz als Neuroprotektivum in besonderen intensivmedizinischen Szenarien wie dem hypoxischen Hirnschaden nach Reanimation.
    Intensivmedizin + Notfallmedizin 01/2010; 47(1):55-58. DOI:10.1007/s00390-009-0032-5